Roots Analysis: 5 Companies Lead GLP-1 Drug Development
A Roots Analysis report identifies five companies at the forefront of developing GLP-1 drugs for type 2 diabetes and obesity treatments.
Roots Analysis released a report in August 2024 identifying the top five companies in the GLP-1 drug market. These drugs, which mimic the action of a gut hormone, offer new treatment avenues for type 2 diabetes and obesity, with ongoing research exploring their potential for other metabolic disorders.
The analysis highlights that the demand for GLP-1 drugs is driven by the rising prevalence of chronic diseases like diabetes and obesity, rapid advancements in research and development, and favorable reimbursement policies, leading to significant industry growth in recent years.
The study examined close to 60 companies engaged in GLP-1 drug development. The top five companies, listed in descending order by the number of unique GLP-1 drugs developed, are:
- Eli Lilly
- D&D Pharmatech
- Novo Nordisk
- Tonghua Dongbao Pharmaceutical
- Vivani Medical
Eli Lilly is identified as a leading player with multiple GLP-1 drugs on the market, including Trulicity® (type 2 diabetes) and Mounjaro® (type 2 diabetes), alongside Zepbound® (obesity). The company also maintains a substantial pipeline with new drugs in clinical development, including dual and triple agonists targeting diabetes, obesity, sleep apnea, heart disease, chronic kidney disease, and NASH.
The report provides a comprehensive overview of the GLP-1 market and future opportunities for companies within the sector over the next 12 years.